FDA Drug Info Rounds, July 2012: Accelerated Approval Program


 

FDA Drug Info Rounds, July 2012: Accelerated Approval Program – The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious diseases, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker that is used in clinical trials as an indirect or substitute measurement that represents a clinically meaningful outcome. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. For more information, please see our website: www.fda.gov [vpdrugs]

 

US Could Save Billions, Lift Black Community by Treating Instead of Jailing

Filed under: drug treatment program statistics

U.S. Could Save Billions, Lift Black Community by Treating Instead of Jailing Drug Users. November 12, 2012 | Posted by Nick Chiles Tagged … According to current statistics, between one-quarter to one-third of black men will be incarcerated at some …
Read more on Atlanta Black Star